Epcoritamab with gentler chemo for older adults with lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs — epcoritamab and a gentler chemo regimen (rituximab-mini CVP) — for older or frailer patients with newly diagnosed aggressive B-cell lymphoma who cannot tolerate standard intensive chemo. The goal is to find a safer but effective treatment option that still controls the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old.
- Have a confirmed diagnosis of diffuse large B-cell lymphoma or a similar aggressive B-cell lymphoma.
- Not have received prior systemic treatment (like chemotherapy) for this lymphoma.
- Be considered unfit for standard anthracycline-based chemo — this includes being 80 or older, being frail by a geriatric assessment, or having heart issues that rule out anthracyclines.
- Have measurable disease (at least one enlarged lymph node or lesion visible on imaging).
- Have adequate kidney, liver, and bone marrow function, and an ECOG performance status of 2 or less (or 3 if it improves to 2 after pre-phase treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.